首页> 外文期刊>Cancers >Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
【24h】

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

机译:靶向肿瘤细胞表面蛋白生物标志物的核酸适体的选择

获取原文
           

摘要

Aptamers are nucleic acids referred to as chemical antibodies as they bind to their specific targets with high affinity and selectivity. They are selected via an iterative process known as ‘selective evolution of ligands by exponential enrichment’ (SELEX). Aptamers have been developed against numerous cancer targets and among them, many tumor cell-membrane protein biomarkers. The identification of aptamers targeting cell-surface proteins has mainly been performed by two different strategies: protein- and cell-based SELEX, when the targets used for selection were proteins and cells, respectively. This review aims to update the literature on aptamers targeting tumor cell surface protein biomarkers, highlighting potentials, pitfalls of protein- and cell-based selection processes and applications of such selected molecules. Aptamers as promising agents for diagnosis and therapeutic approaches in oncology are documented, as well as aptamers in clinical development.
机译:适体是被称为化学抗体的核酸,因为它们以高亲和力和选择性结合其特异性靶标。通过称为“通过指数富集的配体选择性进化”的迭代过程(SELEX)选择它们。已经开发了针对许多癌症靶标的适体,其中包括许多肿瘤细胞膜蛋白生物标记。靶向细胞表面蛋白的适体的鉴定主要通过两种不同的策略进行:基于蛋白质和基于细胞的SELEX,而用于选择的靶标分别是蛋白质和细胞。这篇综述旨在更新针对靶向肿瘤细胞表面蛋白生物标志物的适体的文献,重点介绍基于蛋白质和细胞的选择过程的潜力,陷阱以及此类分子的应用。适体作为在肿瘤学中的诊断和治疗方法的有希望的试剂,以及在临床开发中的适体都有文献记载。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号